

PAPER

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Nanoscale Adv.*, 2025, 7, 7519**Bismuth selenide nanoflowers for internal irradiation combined with photothermal therapy for tumor sensitization and killing**Jiage Gong,^{†a} Qi Wang,^{†b} Ruqi Wang,^{†a} Jianhua Chen,^a Jie Gao,^a
Jiangfeng Du^{†bcd} and Jianguo Li^{*ab}

The radioisotope ^{177}Lu has shown great potential in the treatment of tumors. However, free radioisotopes may cause toxicity to normal tissues and organs. Therefore, it is crucial for enhanced tumor therapy that ^{177}Lu can be retained in tumor tissues by the development of novel delivery systems. However, the efficacy of internal radiotherapy (IRT) is limited by the hypoxic microenvironment induced by the insufficient blood supply in solid tumors. Herein, we synthesized novel ^{177}Lu -labeled bismuth selenide nanoflowers that possess the peculiarity of photothermal conversion and can achieve photothermal therapy (PTT) for tumors under light conditions. Moreover, the amino group of selenocysteine in the outer layer of Bi_2Se_3 can efficiently form covalent bonds with ^{177}Lu , decreasing the side effects of free radioisotopes on normal tissues. These results demonstrate that selenocysteine-modified Bi_2Se_3 nanoflowers ($\text{Bi}_2\text{Se}_3\text{@Sec NFs}$) have the potential for application as radionuclide delivery carriers and radionuclide-photothermal therapy drugs.

Received 24th March 2025

Accepted 22nd August 2025

DOI: 10.1039/d5na00270b

rsc.li/nanoscale-advances**1. Introduction**

Radiotherapy is a cornerstone of solid tumor treatment and includes internal radiotherapy and external radiotherapy.^{1,2} In order to improve radiation sensitization, other treatments, such as surgery³ and chemotherapy,⁴ photothermal therapy,⁵ and photodynamic therapy,^{6–9} need to be combined. One of the main factors limiting the therapeutic effect of radiotherapy is related to the hypoxic tumor microenvironment.^{10,11} If there is sufficient oxygen in tumor tissues, the efficacy of radiotherapy will be improved by enhancing radiation-induced DNA damage.¹² In the past decade, different types of multi-functional nanomaterials were synthesized, which could not only physically sensitize tumors to radiation, but also increase the blood flow in the tumor area through the photothermal conversion effect to reverse the defect of the hypoxic tumor microenvironment.^{13–15} Our previous study has found that

external radiation combined with photothermal therapy could enhance the sensitivity towards tumor cells,¹⁶ but the skin radiation side effect caused by external radiation is still unavoidable.¹⁷ However, isotope therapy, which has a short β -radiation distance (about 2.5 mm), could effectively avoid radiation damage to adjacent normal tissues during radiotherapy.¹⁸ However, how to accurately deliver radioisotopes to tumor tissues remains a challenge.¹⁴

Traditional radioisotopes are connected to targeted peptides through a linker and then injected intravenously for tumor diagnosis and treatment.¹⁹ However, the inevitable off-target effect and poor tumor tissue enrichment efficiency of the isotopes still hinder the clinical application of radioisotope therapy.^{20,21} The development of nano-delivery carriers provides a new strategy for isotope delivery.²² It has been reported that nanomaterials could be used to accurately deliver chemotherapy drugs, genes, small molecule inhibitors, and radioisotopes to the tumor site.^{23,24} Pei Pei *et al.* constructed an inactivated bacterial vector with $^{125}\text{I}/^{131}\text{I}$ labeling ($^{125}\text{I-VNP}/^{131}\text{I-VNP}$) that could retain radioiodine at the tumor site for a long time and deliver it into tumor cells and tumor-associated macrophages (TAMs), thus achieving efficient internal radioisotope therapy.²⁵ Yueping Li *et al.* demonstrated an ^{177}Lu -labeled bioorthogonal nanoprobe for improved MR imaging, differentiating, and downstaging of bladder tumors.²⁶ Xi-Yang Cui *et al.* installed a sulfur(vi) fluoride exchange (SuFEx) chemistry-based linker on radiopharmaceuticals to prevent excessively fast tumor clearance.²⁰ Moreover, nano-drugs can be maximally enriched in the tumor site by intratumoral injection.

^aNational Atomic Energy Agency Nuclear Technology (Nonclinical Evaluation of Radiopharmaceuticals) Research and Development Center, CNNC Key Laboratory on Radiotoxicology and Radiopharmaceutical Preclinical Evaluation, China Institute for Radiation Protection, Taiyuan 030001, China. E-mail: ljj2547@163.com

^bCollege of Pharmacy, Shanxi Medical University, Jinzhong, 030619, Shanxi Province, China. E-mail: dujif@sxmu.edu.cn

^cDepartment of Medical Imaging, Shanxi Key Laboratory of Intelligent Imaging and Nanomedicine, First Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi Province, China

^dCollaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China

[†] These authors contributed equally to this work.

Therefore, the toxic side effects of free radioisotopes on normal tissues could be effectively avoided when the radioisotopes are delivered by nanocarriers and administered by intratumoral injection.

Based on our previous study, the biodegradable selenocysteine-based bismuth selenide nanoflowers ($\text{Bi}_2\text{Se}_3\text{@Sec NFs}$) exhibited excellent biosafety.²⁷ Herein, the amino group of selenocysteine has been found to covalently bind with ^{177}Lu ($t_{1/2} = 6.65$ days). Moreover, the photothermal conversion effect of $\text{Bi}_2\text{Se}_3\text{@Sec NFs}$ could increase the temperature of the tumor area. After the intratumoral injection of ^{177}Lu -labeled $\text{Bi}_2\text{Se}_3\text{@Sec NFs}$, the β -rays emitted by ^{177}Lu could continuously kill tumor cells by the long-term retention effect of nanomaterials in the tumor tissues. At the same time, the γ -rays emitted by ^{177}Lu could also be used for single-photon emission computed tomography (SPECT) imaging of the tumors. This novel study provides a new idea for the precise delivery of ionic isotopes to tumor tissues (Scheme 1).

2. Experimental

Material

The ^{177}Lu isotope was purchased from the China Institute of Atomic Energy. L-Selenocysteine was purchased from J&K Scientific. Bismuth nitrate pentahydrate ($\text{Bi}(\text{NO}_3)_3 \cdot 5\text{H}_2\text{O}$) was purchased from Beijing Chemical Works. HT-29 cells were purchased from Wuhan Pricella Biotechnology Co., Ltd. RPMI Medium 1640 was purchased from Gibco (USA). Every Green Fetal bovine serum was purchased from Tianhang Biotechnology Co., LTD. Penicillin-streptomycin was purchased from SEVEN (Beijing) Biotechnology Co., LTD. PBS, trypsin, Cell

Counting Kit-8, Giemsa stain, and polyformaldehyde fixative were purchased from Solarbio Life Sciences.

Synthesis

L-Selenocysteine aqueous solution, sodium hydroxide aqueous solution, and deionized water were added sequentially to a three-necked flask and thoroughly mixed by sonication. The mixture was then heated to 80 °C. Subsequently, a $\text{Bi}(\text{NO}_3)_3 \cdot 5\text{H}_2\text{O}$ ethylene glycol solution was rapidly injected into a sealed flask, and the reaction was continued for 3 h at 80 °C. After cooling to room temperature, the products were collected by centrifugation and washed three times to obtain $\text{Bi}_2\text{Se}_3\text{@Sec NFs}$.


To perform ^{177}Lu labelling, 300 μCi of ^{177}Lu ($^{177}\text{LuCl}_3$) was mixed with $\text{Bi}_2\text{Se}_3\text{@Sec NFs}$ solution (water, 500 $\mu\text{g mL}^{-1}$) and the mixture was stirred (500 rpm) at room temperature for 24 h. ^{177}Lu -labelled $\text{Bi}_2\text{Se}_3\text{@Sec NFs}$ were then obtained by centrifugation at 8000 rpm for 30 minutes at 4 °C. Subsequently, the labelling rate and radiolabelling stability were determined.

Characterization

A scanning electron microscope was employed to characterize the morphology and size of the nanoflowers. Energy dispersive X-ray spectroscopy and X-ray photoelectron spectroscopy were used to analyze the chemical composition of nanomaterials.

Investigation of the photothermal properties of the nanoflowers

Different concentrations of $\text{Bi}_2\text{Se}_3\text{@Sec NFs}$ solution (50, 100, 200, 400, 600, 800, and 1000 $\mu\text{g mL}^{-1}$) were prepared; 1 mL of each solution was placed in a cuvette and irradiated by a laser



Scheme 1 Schematic of the synthesis of the $\text{Bi}_2\text{Se}_3\text{@Sec}$ nanoflower-labeled radionuclide ^{177}Lu (a). The therapeutic strategy for ^{177}Lu - $\text{Bi}_2\text{Se}_3\text{@Sec NFs}$ combined with photothermal therapy for improving efficacy in the tumor and simultaneously reducing side effects in normal tissues (b).



(808 nm, power 1.0 W cm^{-2}) for 10 minutes. The temperature of the solution was monitored using a thermal infrared imaging camera (Fluke Ti480U). The temperature changes of the samples were recorded every 30 s, and the temperature was plotted against time.

Next, 1 mL of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs solution ($500 \mu\text{g mL}^{-1}$) was placed in a cuvette and irradiated by a laser (808 nm, power 1.0 W cm^{-2}) for 10 minutes, with an interval of 10 min; this was repeated four times. The temperature of the solution was monitored using a thermal infrared imaging camera (Fluke Ti480U). The temperature changes of the samples were recorded every 30 s, and the temperature was plotted against time. An equal volume of deionized water was used as a control under the same experimental conditions.

Then, 1 mL of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs solution ($500 \mu\text{g mL}^{-1}$) was placed in a cuvette and the laser (808 nm, the power was set to 0.5, 1.0, and 1.5 W cm^{-2} , respectively) was used to irradiate the sample for 10 minutes. After cooling to the initial temperature, the temperature of the solution was monitored using a thermal infrared imaging camera. The temperature changes of the samples were recorded every 30 s. An equal volume of deionized water was used as a control under the same experimental conditions.

Cell culture

Cells were cultured in a cell incubator containing 5% CO_2 at 37°C and cultured in RPMI Medium 1640 with 10% (v/v) FBS and 1% (v/v) penicillin/streptomycin. Cells were passaged at 1 day intervals.

Cell survival assay

The relative cell viabilities were evaluated by CCK-8 assay. HT-29 cells were inoculated into 96-well plates at 1×10^4 cells per well. After 24 h of culturing, the old medium was discarded, and different concentrations of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs (0, 5, 10, 20, 40, 60, 80, $100 \mu\text{g mL}^{-1}$) were added and incubated for 24 h. The old medium was discarded, and fresh complete medium containing $10 \mu\text{L}$ CCK-8 was added to each well. After 2 h of incubation, the absorbance value at 450 nm was measured by a microplate reader (Multiskan GO), and then the cell survival rate of different concentration groups was calculated.

Cellular uptake assay

HT-29 cells were inoculated into 6-well plates and treated with PBS, $^{177}\text{LuCl}_3$ (50 μCi), $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs ($25 \mu\text{g mL}^{-1}$), and $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs (50 μCi , $25 \mu\text{g mL}^{-1}$) 24 h later. After incubation for 1, 4, 12, and 24 h, respectively, the cells were rinsed 2–3 times with PBS, then digested and collected in a centrifuge tube. Finally, the radioactivity of the cells was detected by a gamma counter (WIZARD 2480), and the cell uptake rate was calculated.

The clonogenic assay

HT-29 cells were inoculated into a 6-well plate at 2000 cells per well, and treated with the following treatments 24 h later: ① PBS; ② $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs ($25 \mu\text{g mL}^{-1}$); ③ $^{177}\text{LuCl}_3$ (50 μCi);

④ $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs (50 μCi , $25 \mu\text{g mL}^{-1}$). After 24 h, the cells were replaced with fresh complete medium and incubated for 10 to 15 days, with the medium changed every 2 to 3 days. When the clones grew to an appropriate size (colonies of about 50 cells), they were fixed with methanol, stained with 10% Giemsa staining solution, washed, dried, and photographed. Finally, the number of clones was counted, the clone formation rate of cells was calculated, and the therapeutic effect was compared.

DNA double-strand break detection

The DNA double-strand break (DSB) levels were detected by immunofluorescence analysis. HT-29 cells were inoculated on coverslips, and different treatments (① PBS; ② near-infrared radiation (NIR, 1.0 W cm^{-2} , 808 nm); ③ $^{177}\text{LuCl}_3$ (50 μCi); ④ $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs + NIR (50 μCi , $25 \mu\text{g mL}^{-1}$)) were performed after 24 hours of culturing. After incubating the above medium for 24 hours, near-infrared radiation (NIR) was applied. Firstly, 4% paraformaldehyde and 0.3% Triton X-100-PBS buffer were employed to fix and perforate cells. Then, 5% bovine serum albumin (BSA) was added for 1 hour at room temperature. Next, the cells were incubated with antibodies against $\gamma\text{-H2AX}$ overnight at 4°C and Cy3-labeled anti-rabbit IgG for 2 hours at room temperature, sequentially. Finally, the nuclei were stained with DAPI and sealed with 10% glycerol. Fluorescence images were captured using a Nikon Ti-A1 laser confocal microscope. Representative images are shown.

Animals

All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of the China Institute for Radiation Protection and approved by the Animal Ethics Committee of the China Institute for Radiation Protection (CIRP-IACUC-(G)2023331). Female experimental animals, aged 7–8 weeks, with a specific pathogen-free (SPF) grade and an average body weight of $20 \pm 2 \text{ g}$, were obtained from Changzhou Cavens Laboratory Animal Co., Ltd. The animals were housed in a controlled environment at a temperature of 25°C and 50% air humidity.

Biodistribution of drugs

The HT-29 cell line was selected to establish the tumor animal model. When the subcutaneous tumor volume reached about 100 mm^3 , 24 tumor-bearing mice were randomly divided into 8 groups, respectively, with 3 mice in each group: ① $^{177}\text{LuCl}_3$ (2 h), ② $^{177}\text{LuCl}_3$ (24 h), ③ $^{177}\text{LuCl}_3$ (48 h), ④ $^{177}\text{LuCl}_3$ (10 d), ⑤ $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs (2 h), ⑥ $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs (24 h), ⑦ $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs (48 h), ⑧ $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs (10 d). Each group of mice was injected with $^{177}\text{LuCl}_3$ and $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3$ NFs *via* intratumoral injection, respectively, and the radioactivity was 100 μCi . The heart, liver, spleen, lung, kidney, stomach, intestine, and tumors were taken at the corresponding time points. Subsequently, the organ radioactivity was detected by a gamma counter.



The effects of radionuclide therapy combined with photothermal therapy on tumor treatment

The HT-29 cell line was selected to establish the tumor animal model. When the subcutaneous tumor volume reached about 70 mm³, the tumor-bearing nude mice were randomly divided into 7 groups (① Control group; ② Bi₂Se₃@Sec NFs (1.5 mg kg⁻¹); ③ NIR (1.0 W cm⁻², 808 nm); ④ ¹⁷⁷LuCl₃ (300 μCi); ⑤ ¹⁷⁷Lu-Bi₂Se₃@Sec NFs (300 μCi, 1.5 mg kg⁻¹); ⑥ Bi₂Se₃@Sec NFs + NIR (1.5 mg kg⁻¹, 1.0 W cm⁻², 808 nm); ⑦ ¹⁷⁷Lu-Bi₂Se₃@Sec NFs + NIR (300 μCi, 1.5 mg kg⁻¹, 1.0 W cm⁻², 808 nm)), with 3 mice in each group.

As shown in Fig. 2, mice in groups ② and ⑥ were injected with Bi₂Se₃@Sec NFs solution, mice in groups ⑤ and ⑦ were injected with ¹⁷⁷Lu-Bi₂Se₃@Sec NFs solution, and mice in group ④ were injected with ¹⁷⁷LuCl₃ solution by intratumoral injection. Then, groups ③, ⑥, and ⑦ received 1 W cm⁻², 808 nm laser irradiation for 10 min, and the local tumor temperature changes were monitored by thermal imaging. At the end of treatment, the body weight and tumor volume of the mice were monitored every other day until day 20 after treatment. Whole blood was collected from mice by enucleation of the eyeballs, and the mice were sacrificed by cervical dislocation. The important organs of the mice (including the heart, liver, spleen, lungs, and kidneys) as well as their femur and

tumors were collected and weighed to evaluate the therapeutic effect of different groups of tumors.

2. Results and discussion

Characterization and radiochemical properties of nanocarriers

In our previous report, the Bi₂Se₃@Sec nanoflowers exhibited good biosafety and microwave sensitization effects. The typical scanning electron microscopy (SEM) images shown in Fig. 1a reveal that Bi₂Se₃@Sec NFs are in the shape of flower clusters (Fig. 1a) with a diameter of about 500–1000 nm. Energy-dispersive X-ray spectroscopy (EDS) and X-ray photoelectron spectroscopy (XPS) results for Bi₂Se₃@Sec NFs further confirmed that the nanoflowers were composed of Bi and Se elements (Fig. 1b and c). The labeling yield of ¹⁷⁷Lu was 88.15% ± 1% and it showed good radiostability in PBS and serum (37 °C) (Fig. 1d). These experimental results indicate the successful synthesis and high purity of Bi₂Se₃@Sec NFs, and their isotope labeling.

Photothermal conversion effect of Bi₂Se₃@Sec NFs *in vitro*

As shown in Fig. 2a and c, under the irradiation of the 808 nm laser (power density 1.0 W cm⁻²), the temperature of the




Fig. 1 (a) SEM image of Bi₂Se₃@Sec NFs (scale bar: 5 μm). (b) EDS analysis of Bi₂Se₃@Sec NFs. (c) XPS analysis of Bi₂Se₃@Sec NFs. (d) Radiological stability curves of ¹⁷⁷Lu-Bi₂Se₃@Sec NFs in PBS/FBS.






Fig. 2 (a) The infrared thermal images of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs with various concentrations of dH_2O at different time points under 808 nm laser irradiation (1.0 W cm^{-2}). (b) The comparison of temperature elevation between $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs ($500 \mu\text{g mL}^{-1}$) and dH_2O under 808 nm laser irradiation at different powers. (c) The heating curves of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs with different concentrations under 808 nm laser irradiation (1.0 W cm^{-2}). (d) Rise and fall curves of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs ($500 \mu\text{g mL}^{-1}$) for five laser irradiation cycles under 808 nm laser irradiation (1.0 W cm^{-2}).

$\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs aqueous solution increased with irradiation time, while the temperature of the control group had no significant change. Under the same concentration of nanoflowers ($500 \mu\text{g mL}^{-1}$) with different laser power, the temperature of the aqueous solution of nanoflowers rose rapidly with the increase of laser power, while the temperature of the aqueous solution in the control group did not change

significantly (Fig. 2b). $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs nanoflowers ($600 \mu\text{g mL}^{-1}$) increased to 65.4°C after 10 minutes of laser (1.0 W cm^{-2}) exposure, an increase of 41.4°C from the original temperature. Further experiments showed that the photothermal conversion ability of the $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs aqueous solution did not decrease after 4 cycles of continuous heating




Fig. 3 (a) Cell viability of HT29 cells after treatment with $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs. (b) *In vitro* cellular uptake of $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs and $^{177}\text{LuCl}_3$. (c) Cell cloning experiment of HT-29 cells after different treatments. (d) The biological distribution of free ^{177}Lu and $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs in mice was determined at different times after intratumoral injection.

and cooling, indicating its stable photothermal conversion performance (Fig. 2d).

Cell culture experiment

For further research, the HT-29 cells were employed to evaluate the cytotoxicity of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs. After incubation with different concentrations of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs for 24 h, the HT-29 cell viability was evaluated by CCK-8 assay. The results showed that the cell viability remained above 90% when the concentration of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs reached $100 \mu\text{g mL}^{-1}$, indicating that $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs had no obvious toxicity toward the cells (Fig. 3a). In the cell uptake experiment, the radioactivity of different groups was detected 1, 4, 12, and 24 h after treatment (Fig. 3b). The results showed that the intracellular radioactivity in the $^{177}\text{LuCl}_3$ group was significantly lower than that in the $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs ($p < 0.05$), indicating that $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs had higher cellular uptake efficiency. In the clone formation assay, there was no difference in the clone formation rate between the $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs treatment and the control group, further indicating the good safety of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs at the cellular level (Fig. 3c). In contrast, the clone formation rate of $^{177}\text{LuCl}_3$ group was 53.26%, and that of $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs was 20.73%, which was significantly different ($p < 0.05$), indicating that $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs had a significant effect on inhibiting the growth of tumor cells. Confocal microscopy was used to detect $\gamma\text{-H2AX}$ foci in the cell nuclei as a quantitative marker of DNA double-strand breaks (Fig. S1); prominent, higher-density $\gamma\text{-H2AX}$ foci were observed in the $^{177}\text{Lu}-$

$\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs + NIR group when compared to the group with $^{177}\text{LuCl}_3$ or NIR alone. The density of $\gamma\text{-H2AX}$ foci was the highest in the synergistic NIR+ $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs group. These results suggest that $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs-mediated PTT/IRT combined therapy provides a means to efficiently kill cancer cells.

The organ radioactivity was measured at 2 h, 24 h, 48 h, and 10 d after intratumoral injection (Fig. 3d). The results showed that the radioactivity of $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs in the tumor was always at a high level, and a small amount of radioactive material accumulated in the liver and kidney. Over time, normal tissues showed little radioactivity. Compared with free ^{177}Lu , $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs were better retained in the tumor at different time points.

The evaluation of $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs combined with photothermal therapy *in vivo*

Encouraged by the effects of $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs *in vitro*, we further investigated the therapeutic effect *in vivo* by intratumoral injection. As shown in Fig. S2 and S3, the temperature of the tumor region changed from 38.8 to 51.7 °C under the 808 nm laser (1 W cm^{-2}) irradiation for 10 min, while the control group treated with PBS had no obvious temperature increase. Compared to the control group, the inhibitory effect of the $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs + NIR group was better after 20 days. At the end of treatment, tumors were dissected, weighed, and photographed (Fig. 4b and d). The tumor weights and sizes were the least in the different treatment groups, which confirmed the




Fig. 4 (a) The body weight curves of different groups of mice during treatment time. (b) The images of isolated tumors. (c) Tumor weights in different treatment groups at the time of dissection (day 20). (d) The tumor growth curves of different groups of mice during treatment time. (e) Hematological parameters of different groups. (f) The pathological characteristics of representative tumor tissues in different groups: H&E (scale bar: 200 μm).



synergistic effect of PTT and radionuclide therapy. In the hematoxylin and eosin (HE) staining assay, the tumor tissues of the $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs + NIR group showed varying degrees of necrosis, vacuolar degeneration in the cytoplasm, reduced tumor cell clusters, increased intercellular space, and sparse distribution of tumor cells compared with the control group. The nuclei were variable in size and the degree of staining, and there was multifocal or flaky tumor cell necrosis. In the ^{177}Lu and PTT group, only partial regions of tumor tissue were destroyed. As shown in Fig. 4a, there was no significant change in body weight between the control group and all treatment groups during the 20 days of treatment, indicating that the nanomedicine had no significant side effects on mice. According to the results of the blood routine test, there was no significant difference in WBC, RBC, LYM, and other indices between all treatment groups and the control group, indicating that the materials and treatment methods did not cause obvious toxic side effects.

4. Conclusions

In summary, we have developed a strategy to sensitize and kill tumors by combining a ^{177}Lu -labeled nanoradioenhancer with photothermal therapy. On the one hand, $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs have good biocompatibility and photothermal properties, and radiation stability under the radionuclide irradiation. This suggests that the $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs can be good photothermal agents for tumor photothermal therapy. On the other hand, we stabilized $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs with the radioactive nuclide ^{177}Lu through ion exchange reactions. The uptake of $^{177}\text{Lu}-\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs on HT-29 cells and the retention ability in tumor tissue were all higher than those of the $^{177}\text{LuCl}_3$ group (Fig. 3b and d). In this study, $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs-loaded ^{177}Lu combined with photothermal therapy can further improve the tumor inhibition rate compared with single treatments. With the further exploration of methods and the adjustment of the radionuclide dose, $\text{Bi}_2\text{Se}_3@\text{Sec}$ NFs loaded with ^{177}Lu radionuclide and combined with photothermal therapy is expected to become a new method to effectively kill cancer cells and protect normal tissues and organs as much as possible.

Author contributions

J.-G. G., Q. W., R.-Q. W.: Writing-original draft and investigation. J.-H. C., J. G.: Investigation and data curation. J.-F. D., J.-G. L.: Project administration, supervision, and writing review and editing.

Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could influence the work reported in this paper.

Data availability

The data supporting this article have been included as part of the SI. See DOI: <https://doi.org/10.1039/d5na00270b>.

Acknowledgements

This work was supported by the Social Development Projects of Key R&D Program in Shanxi Province (202303021221223) and CIRP Open Fund of Radiation Protection Laboratories (CIRP-CAEA20240201).

References

- 1 J.-F. Chatal and C. A. Hoefnagel, *Lancet*, 1999, **354**, 931–935.
- 2 L. Y. Gong, Y. J. Zhang, C. C. Liu, M. Z. Zhang and S. X. Han, *Int. J. Nanomed.*, 2021, **16**, 1083–1102.
- 3 M. C. van Maaren, L. de Munck, G. H. de Bock, J. J. Jobsen, T. van Dalen, S. C. Linn, P. Poortmans, L. J. A. Strobbe and S. Siesling, *Lancet Oncol.*, 2016, **17**, 1158–1170.
- 4 J. X. Dai, B. Zhang, Y. X. Su, Y. F. Pan, Z. K. Ye, R. Cai, G. J. Qin, X. Y. Kong, Y. Y. Mo, R. J. Zhang, Z. C. Liu, Y. Xie, X. L. Ruan and W. Jiang, *JAMA Oncol.*, 2024, **4**, 456–463.
- 5 Y. Yong, X. J. Cheng, T. Bao, M. Zu, L. Yan, W. Y. Yin, C. C. Ge, D. L. Wang, Z. J. Gu and Y. L. Zhao, *ACS Nano*, 2015, **9**, 12451–12463.
- 6 W. Rao, Z. S. Deng and J. Liu, *Crit. Rev. Bioeng.*, 2010, **38**, 101–116.
- 7 R. B. Mokhtari, T. S. Homayouni, N. Baluch, E. Morgatskaya, S. Kumar, B. Das and H. Yeger, *Oncotarget*, 2017, **8**, 38022–38043.
- 8 Y. W. Wang, K. Ma, M. M. Kang, D. Y. Yan, N. Niu, S. S. Yan, P. P. Sun, L. Z. Zhang, L. J. Sun, D. Wang, H. Tan and B. Z. Tang, *Chem. Soc. Rev.*, 2024, **53**, 12014–12042.
- 9 Y. Chao, L. G. Xu, C. Liang, L. Z. Feng, J. Xu, Z. L. Dong, L. L. Tian, X. Yi, K. Yang and Z. Liu, *Nat. Biomed. Eng.*, 2018, **2**, 611–621.
- 10 F. Mudassar, H. Shen, K. M. Cook and E. Hau, *J. Med. Imaging Radiat. Oncol.*, 2022, **66**, 560–574.
- 11 D. C. Singleton, A. Macann and W. R. Wilson, *Nat. Rev. Clin. Oncol.*, 2021, **18**, 751–772.
- 12 Z. Chen, F. F. Han, Y. Du, H. Q. Shi and W. C. Zhou, *Signal Transduction Targeted Ther.*, 2023, **8**, 70.
- 13 L. Y. Gong, Y. J. Zhang, C. C. Liu, M. Z. Zhang and S. X. Han, *Int. J. Nanomed.*, 2021, **16**, 1083–1102.
- 14 G. S. Song, L. Cheng, Y. Chao, K. Yang and Z. Liu, *Adv. Mater.*, 2017, **29**, 1700996.
- 15 M. Varzandeh, L. Sabouri, V. Mansouri, M. Gharibshahian, N. Beheshtizadeh, M. R. Hamblin and N. Rezaei, *Bioeng. Transl. Med.*, 2023, **8**, e10498.
- 16 J. F. Du, Z. J. Gu, L. Yan, Y. Yong, X. Yi, X. Zhang, J. Liu, R. F. Wu, C. C. Ge, C. Y. Chen and Y. L. Zhao, *Adv. Mater.*, 2017, **29**, 1701268.
- 17 K. Wang and J. E. Tepper, *Ca-Cancer J. Clin.*, 2021, **71**, 437–454.
- 18 U. Hennrich and M. Eder, *Pharmaceuticals*, 2022, **15**, 1292.



- 19 L. Chen, X. Y. Zhong, X. Yi, M. Huang, P. Ning, T. Liu, C. C. Ge, Z. F. Chai, Z. Liu and K. Yang, *Biomaterials*, 2015, **66**, 21–28.
- 20 X. Y. Cui, Z. Li, Z. Kong, Y. Liu, H. Meng, Z. H. Wen, C. L. Wang, J. Y. Chen, M. X. Chen, Y. Y. Li, J. Y. Gao, W. J. Zhu, Z. X. Hao, L. Huo, S. Y. Liu, Z. Yang and Z. B. Liu, *Nature*, 2024, **630**, 206–213.
- 21 E. O. Aboagye, T. D. Barwick and U. Haberkorn, *Ca-Cancer J. Clin.*, 2023, **73**, 255–274.
- 22 L. M. Sun, H. M. Liu, Y. Q. Ye, Y. Lei, R. Islam, S. M. Tan, R. S. Tong, Y. B. Miao and L. L. Cai, *Signal Transduction Targeted Ther.*, 2023, **8**, 418.
- 23 X. Z. Zhu and S. L. Li, *Mol. Cancer*, 2023, **22**, 94.
- 24 S. Raj, S. Khurana, R. Choudhari, K. K. Kesari, M. A. Kamal, N. Garg, J. Ruokolainen, B. C. Das and D. Kumar, *Semin. Cancer Biol.*, 2021, **69**, 166–177.
- 25 P. Pei, Y. Zhang, Y. C. Jiang, W. H. Shen, H. Chen, S. Yang, Y. X. Zhang, X. Yi ang and K. Yang, *ACS Nano*, 2022, **16**, 11325–11337.
- 26 Y. P. Li, S. S. Shan, R. R. Zhang, C. P. Sun, X. L. Hu, J. D. Fan, Y. Wang, R. X. Duan and M. Y. Gao, *ACS Nano*, 2024, **18**, 17209–17217.
- 27 L. Gao, H. L. Yan, S. Zhu, X. C. Wang, Y. Tan, J. F. Du, D. P. Feng, H. Zhang and Z. J. Gu, *Nano Today*, 2021, **41**, 101314.

